AIFM1 Cardiac Phenotype in Females

> Research explainer: This briefing examines verified primary research published 59 days before the briefing date. It is not a same-day research update and does not provide medical advice.

Evidence

The source reports a female child with infantile-onset mitochondrial encephalomyopathy who carried a heterozygous, de novo AIFM1 variant, c.506C>T (p.Pro169Leu). AIFM1 encodes a mitochondrial oxidoreductase with roles in mitochondrial function, redox control, and non-caspase-dependent cell death. The report characterizes AIFM1-related disease as clinically heterogeneous and notes overlap with other mitochondrial disorders. [pmid:42329587]

Cardiac findings changed over longitudinal follow-up. Echocardiography at 8 months showed marked left-ventricular hypertrophy while systolic function was preserved. By 2.5 years, the report describes left-ventricular dilation with systolic dysfunction and initiation of heart-failure therapy. Thus, the observed sequence in this child was hypertrophy followed by dilation and impaired systolic function. [pmid:42329587]

The authors state that cardiac involvement had previously been reported in four patients with AIFM1 variants, primarily as ventricular hypertrophy. They also state that the clinical course and prognosis of AIFM1-associated cardiac involvement remain incompletely understood. Their literature review places this child's course within a proposed phenotype that can include early-onset hypertrophy and later ventricular dilation and heart failure. [pmid:42329587]

The report includes markedly skewed X-inactivation of 98:2 in the child and concludes that a heterozygous AIFM1 variant can manifest clinically in females. It presents this case as the first affected female reported with this combination of heterozygous AIFM1 variation, mitochondrial encephalomyopathy, and cardiomyopathy. These observations extend the reported phenotype, but they do not by themselves determine why manifestations occur in every female carrier or how often they occur. [pmid:42329587]

Analysis — Longitudinal phenotype interpretation

This is most usefully read as a phenotype-expansion and longitudinal-observation report, not as a study that establishes a typical disease trajectory. Its central contribution is the documented transition from preserved systolic function with marked left-ventricular hypertrophy at 8 months to left-ventricular dilation and systolic dysfunction by 2.5 years in one heterozygous female child. That sequence matters because prior AIFM1 cardiac cases cited by the authors were primarily described as ventricular hypertrophy, whereas this report records a later dilated, heart-failure-associated phenotype. [pmid:42329587]

The genetic context also matters to interpretation. The variant was de novo and heterozygous, and the report found extremely skewed X-inactivation. Together, those case-specific findings provide a plausible context for disease manifestation in this female child, consistent with the authors' conclusion that females with heterozygous AIFM1 variants can be affected. They do not establish a general relationship between any particular X-inactivation pattern, variant, and cardiac outcome. [pmid:42329587]

The source's monitoring emphasis should be understood as the authors' recommendation arising from the reported case and literature review. They highlight early recognition and careful cardiac monitoring in affected individuals, potentially including female variant carriers. The report does not test a surveillance strategy, compare management approaches, or measure whether monitoring changes outcomes. It therefore supports awareness of a possible cardiac manifestation, while leaving effectiveness and optimal implementation unanswered. [pmid:42329587]

Limitations

This is a single-patient case report accompanied by a literature review. It cannot estimate incidence, define prognosis, or demonstrate that the hypertrophy-to-dilation sequence is expected for AIFM1-associated disease. The report identifies an association between the AIFM1 variant and the cardiac phenotype, but it does not establish that the variant alone caused the phenotype. The source also supplies no population-level evidence, controlled comparison, or clinical-guidance study. Its stated uncertainty about the condition's course, progression risk, and long-term prognosis is therefore consequential when interpreting the case. [pmid:42329587]

The report's detailed observations are strongest for the individual described: timing of echocardiographic findings, genetic results, and the subsequent use of heart-failure therapy. Broader statements about females, variant carriers, and the range of cardiac outcomes remain constrained by the very small published experience described by the authors. [pmid:42329587]